biotech · Neuroblastoma · Hyperinflammation, Sepsis · AXIM
AXIM Biotechnologies
AXIM BIOTECHNOLOGIES, INC.
AXIM Biotechnologies trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.
18 East 50th Street, 5 Floor, New York, NY 10022, US HQ
2011 Founded
7 Employees
Public company Type
AXIM · NYSE Ticker
Company details
- Status
- Public
- HQ
- 18 East 50th Street, 5 Floor, New York, NY 10022, US
- Founded
- 2011
- Employees
- 7
- Programs
- 20
- Drugs
- 52
- Patents
- 138
AXIM Biotechnologies clinical trials
Registry index of 20 ClinicalTrials.gov studies linked to AXIM Biotechnologies programs — each row shows trial ID, program name, phase, status, and indication.
AXIM Biotechnologies trial registry — 20 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for AXIM Biotechnologies.
-
PS22PET — Phase 2
Clinical update -
INFLUENCE — Phase 3
Clinical update -
IVEMEND for Delayed chemotherapy induced na… — Phase 3
Clinical update -
Ziftomenib for Acute Myeloid Leukemia, Mixed P… — Phase 1
Clinical update -
SP_MH20VYX — Phase 1
Clinical update -
SP_MH19PRO — Phase 3
Clinical update -
SIOPEN-Pilot01 — Phase 2
Clinical update -
HEM-iSMART sub C — Phase 2
Clinical update
Trial registry
-
CTIS ↗ - 2022-501866-22-00CTIS ↗
HEM-iSMART - Sub B
Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
- 2022-501867-42-01CTIS ↗
HEM-iSMART sub C
Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory
-
CTIS ↗ - 2023-505262-28-00CTIS ↗
Ziftomenib for Acute Myeloid Leukemia, Mixed P…
Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphocytic Leukemia
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2023-507598-16-00CTIS ↗
ONC201, Paxalisib
Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs)
-
CTIS ↗ -
CTIS ↗ -
CTIS ↗ - 2024-513412-10-00CTIS ↗
BrigaPED ITCC-098
Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors
-
CTIS ↗ - 2024-517846-32-00CTIS ↗
IVEMEND for Delayed chemotherapy induced na…
Delayed chemotherapy induced nausea and vomiting (CINV)
- 2024-517922-24-00CTIS ↗
WT1-loaded CBDC Vaccine
AML: Acute Myeloid Leukemia/ cancer of blood and bone marrow
- 2025-521180-13-00CTIS ↗
ONC206 Powder
Diffuse Midline Glioma (DMG), and Other Recurrent Primary Malignant Central Nervous System (CNS) Tumors
-
CTIS ↗ -
CTIS ↗ -
CT.gov ↗